Igene Biotechnology, Inc. / Fundamentals
Income statement
- Net revenue
€4.10K - Cost of goods sold
-€30.74K - Gross profit
€34.84K - SG&A expenses
€804.83K - R&D expenses
€1.74M - EBITDA
-€390.46K - D&A
€118.55K - EBIT
-€1.99M - Interest expenses
€55.06K - EBT
-€1.22M - Tax expenses
€1.52M - Net income
-€2.02M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€968.93K - Changes in working capital
€1.44M - Operating cash flow
-€1.43M - Capex
-€14.18K - Other investing cash flow
€297.68 - Net investing cash flow
€14.48K - Total cash dividends paid
€0.00 - Issuance of common stock
€0.00 - Debt repayment
€0.00 - Other financing cash flow
€0.00 - Net financing cash flow
€0.00 - Foreign exchange effects
€10.99K - Net change in cash
-€1.41M - Cash at end of period
€229.69K - Free cash flow
-€1.45M
Balance sheet
- Cash and cash equivalents
€229.69K - Cash and short-term investments
€229.69K - Total receivables
€1.85M - Inventory
€0.00 - Other current assets
€64.82 - Total current assets
€2.08M - Property, plant & equipment
€637.12K - Goodwill
€0.00 - Intangible assets
€127.66K - Long-term investments
€0.00 - Other non-current assets
€63.47K - Total non-current assets
€828.26K - Total assets
€2.91M - Accounts payable
€0.00 - Short-term debt
€1.38M - Other current liabilities
€441.08K - Total current liabilities
€1.82M - Long-term debt
€4.88M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€209.69K - Total non-current liabilities
€5.09M - Total liabilities
€6.91M - Common stock
€13.35M - Retained earnings
-€46.79M - Other equity
€44.75K - Total equity
-€4.00M - Total liabilities and shareholders' equity
€2.91M
Company information
- Market capitalization
€13.35K - Employees
18 - Enterprise Value
€5.52M
Company ratios
- Gross margin
-
850.3% Much better than peer group: 25.7% - EBITDA margin
-
-9,529.0% Much worse than peer group: 14.5% - EBIT margin
-
-48,535.0% Much worse than peer group: 4.4% - EBT margin
-
-29,668.6% Much worse than peer group: 3.1% - Net margin
-
-49,414.7% Much worse than peer group: -0.8% - ROE
-
50.7% Much better than peer group: -439.4% - ROA
-
-69.6% Much worse than peer group: 312.0% - Asset turnover
-
0.1% Much worse than peer group: 12,296.0% - FCF margin
-
-34,666.5% Much worse than peer group: -1.0% - FCF yield
-10,638.7% - Efficiency ratio
9,629.0% - Net sales per employee
-
€227.64 - Net income per employee
-
-€112.49K